The Psychedelics Landscape: A Primer for Cannabis Communicators

A few years into running Marino's cannabis practice, I started noticing something at every industry conference: more hallway conversations about psychedelics than about cannabis itself. Investors asking about it. Operators wondering if it's the next category to build in. Reporters who cover cannabis quietly building out a psychedelics beat on the side.

Nobody was wrong to notice. The two industries share a regulatory history, a stigma problem, and, increasingly, the same audience of investors and operators looking for what's next. What most people in cannabis don't have yet is a working knowledge of where psychedelics actually stands right now, legally and structurally. That's what this is.

Start With the Vocabulary

It gets used loosely, so it's worth being precise. Psilocybin, the compound in what's commonly called magic mushrooms, is furthest along a legal pathway right now. MDMA and LSD are moving through federal clinical trials. Ketamine, not technically a classic psychedelic but grouped in with the space by nearly everyone, is already legal and prescribed off-label at clinics across the country. Ibogaine is newer to the legislative conversation and further behind. None of these compounds share a single legal status, which is the first thing that trips people up coming from cannabis, where the plant itself was the whole conversation.

Where Things Actually Stand

Oregon and Colorado both have licensed, operating psilocybin service centers today. New Mexico's program is set to go live this December. Connecticut just signed an expanded pilot into law, and Colorado added a research pilot for ibogaine on top of its existing psilocybin framework. More than half the states in the country have some form of psychedelics legislation pending, most of it aimed at research authorization or pilot programs rather than full legalization.

Federally, the pace picked up meaningfully this year. An executive order in April directed the FDA and DEA to speed up review of psychedelic compounds for serious mental health conditions. That same month, the FDA issued priority review vouchers to three psychedelic drug programs — COMPASS Pathways' psilocybin treatment for depression, Usona Institute's psilocybin program, and Transcend Therapeutics' PTSD treatment — aimed at shortening their review timelines. The agency has a public hearing on psychedelic drugs scheduled for September, the kind of hearing that tends to set the tone for the following year of policy.

The Cannabis Parallel, and Where It Breaks

I wrote about the deeper version of this parallel for GreenState earlier this year, but the short version matters here too: legalization moves fast, governance moves slow. Cannabis proved that. Ballot initiatives and legislative votes can shift a state's legal status in a single election cycle. Building a functioning system underneath that vote, licensing structures, banking access, tax frameworks, equity programs that actually work, takes years longer, and some of it still isn't solved a decade later in states that legalized early.

Psychedelics is entering that same gap, on a different clock. The framing is different too. Cannabis built consumer markets first and answered to medical use later. Psychedelics is doing the opposite, moving through clinical trials and therapeutic frameworks before anything resembling a retail conversation. That changes who the stakeholders are. Instead of state cannabis control boards, it's the FDA, research institutions, and insurers. Instead of dispensary licensing fights, the access question is what a supervised session costing thousands of dollars actually means for who reform is designed to serve.

Same lesson, different mechanism: momentum opens the door. What gets built afterward decides who walks through it.

What This Means for Communicators

This is the part that actually matters for anyone doing comms work in or around cannabis. The media landscape for psychedelics right now looks a lot like cannabis did a decade ago, split between two audiences that don't always read the same outlets. One side is clinical: medical journals, health reporters, an audience that wants trial data and safety framing. The other is cultural, and the stigma hasn't fully lifted, so coverage still swings toward skepticism or spectacle faster than cannabis coverage does today.

Cannabis communicators already know how to operate in that split. Speaking credibly to a health reporter and a lifestyle reporter in the same week, building a narrative that survives contact with a still-uncertain federal position, telling a founder's story without overpromising a treatment outcome, all of that is the exact muscle cannabis PR has been building for a decade. It transfers directly. The compounds and the regulatory bodies are different. The communications problem is not.

As we continue to build out our recently rebranded Cannabis, Psychedelics and Emerging Industries practice, we’ll be tracking this landscape here going forward, the same way we've tracked cannabis media, cannabis events, and cannabis PR strategy for years. Consider this the starting point.